.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
Colorcon
Queensland Health
US Army
Farmers Insurance
McKinsey
Harvard Business School
Cantor Fitzgerald
Covington

Generated: September 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Amlodipine salt forms and processes for preparing them
Abstract:Amlodipine besylate forms are described, including amlodipine besylate hydrates and novel amlodipine besylate anhydrates. A method of making various amlodipine besylate forms from an aqueous medium as well as the use of the same as a calcium channel blocker are described.
Inventor(s): Ettema; Gerrit J. B. (Nijmegen, NL), Hoorn; Hans (Nijmegen, NL), Lemmens; Jacobus M. (Nijmegen, NL)
Assignee: Synthon BV (Nijmegen, NL)
Application Number:10/300,003
Patent Claims: 1. A crystalline amlodipine besylate monohydrate.

2. The amlodipine besylate monohydrate according to claim 1, having a melting point on differential scanning calorimetry (DSC) within the range of 92-104.degree.C.

3. The amlodipine besylate monohydrate according to claim 1, having a purity of at least 99%.

4. The amlodipine besylate monohydrate according to claim 1, which exhibits an IR spetra corresponding to FIG. 6.

5. The amlodipine besylate monohydrate according to claim 1, which exhibits an x-ray powder diffraction pattern corresponding to FIG. 9C.

6. The amlodipine besylate monohydrate according to claim 1, which is in the form of particles having an average particle size of 100 microns or less.

7. The amlodipine besylate monohydrate according to claim 6, wherein said particles have an average particle size of 50 microns or less.

8. The amlodipine besylate monohydrate according to claim 7, which is in the form of particles having an average particle size of 10 microns or less.

9. A pharmaceutical composition comprising 1 to 20 mg of crystalline amlodipine besylate monohydrate, microcrystalline cellulose, sodium starch glycollate, and magnesium stearate.

10. The pharmaceutical composition according to claim 9, which is in the form of a tablet.

11. The pharmaceutical composition according to claim 10, which consists essentially of crystalline amlodipine besylate monohydrate, microcrystalline cellulose, sodium starch glycollate, and magnesium stearate.

12. The pharmaceutical composition according to claim 11, wherein said crystalline amlodipine besylate monohydrate exhibits an JR spectra corresponding to FIG. 6.

13. The pharmaceutical composition according to claim 11, wherein said crystalline amlodipine besylate monohydrate exhibits an x-ray powder diffraction pattern corresponding to FIG. 9C.

14. The pharmaceutical composition according to claim 11, wherein said crystalline amlodipine besylate monohydrate are particles having an average particle size of 50 microns or less.

15. The pharmaceutical composition according to claim 11, wherein said crystalline amlodipine besylate monohydrate are particles having an average particle size of 10 microns or less.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Moodys
Covington
US Army
QuintilesIMS
US Department of Justice
Accenture
Chubb
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot